Furthermore, AML cell lines with wild type FLT3 show a paradox phosphorylation and thereby activation of the ERK2 (MAPK1) pathway, possibly explaining the resistance of sorafenib in FLT3-WT AML cell lines (36). This evidence concerns the gene MAPK1 and acute myeloid leukemia.